首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >In vitro and in vivo evaluation of 10-hydroxycamptothecin-loaded poly(n-butyl cyanoacrylate) nanoparticles prepared by miniemulsion polymerization
【24h】

In vitro and in vivo evaluation of 10-hydroxycamptothecin-loaded poly(n-butyl cyanoacrylate) nanoparticles prepared by miniemulsion polymerization

机译:通过微乳液聚合制备的10-羟基胺蛋白负载的聚(正丁基氰基丙烯酸酯)纳米颗粒的体外和体内评价

获取原文
获取原文并翻译 | 示例
           

摘要

In this paper, 10-hydroxycamptothecin (HCPT)-loaded poly (n-butyl cyanoacrylate) nanoparticles (HCPT-PBCA-NPs) co-modified with polysorbate 80, soybean phospholipids, and polyethylene glycol (100) monostearate were successfully prepared via miniemulsion polymerization, and were characterized for particle size, morphology, zeta potential, encapsulation efficiency (EE) and drug loading capacity (DL). The chemical structure of HCPT-PBCA-NPs and the state of HCPT in the PBCA-NPs were investigated by DSC, FTIR and H-1 NMR. Additionally, drug release, cytotoxicity, cellular uptake capacity, cellular uptake mechanism, and in vivo behavior of NPs were investigated as well. The particles were 92.7 nm in size with a high EE of 94.24%. FFIR, H-1 NMR, and DSC demonstrated complete polymerization of BCA monomers and the drug was in a molecular or amorphous form inside the NPs. In vitro release of the drug from HCPT-PBCA-NPs exhibited sustained-release and less than 60% of HCPT was released from the NPs within 24h of dialysis. Cellular uptake study displayed that Caco-2 cell uptake of NPs was governed by active endocytosis, clathrin- and caveolin-mediated process, and increased with the increase of the NPs concentration and the time. The pharmacokinetic study in rats showed that encapsulation of HCPT into PBCA-NPs increased the C-max and AUC(0-t) about 6.52 and 7.56 times, respectively, in comparison with the HCPT suspension. It was concluded that HCPT loaded PBCA-NPs prepared by miniemulsion polymerization could be promising in oral drug delivery. (C) 2017 Elsevier B.V. All rights reserved.
机译:本文通过微乳液聚合成功制备了用聚山梨醇酯80,大甲磷脂和聚乙二醇(100)单静态异晶酸酯共改变的10-羟基氨基(HCPT)加载的聚(正丁基氰基丙烯酸酯)纳米颗粒(HCPT-PBCA-NPS)纳米颗粒(HCPT-PBCA-NPS)。 ,并被特征在于粒度,形态,Zeta电位,包封效率(EE)和药物负载能力(DL)。通过DSC,FTIR和H-1 NMR研究了HCPT-PBCA-NPS的化学结构和PBCA-NPS中的HCPT状态。另外,还研究了药物释放,细胞毒性,细胞摄取能力,细胞吸收机制和NPS的体内行为。颗粒的尺寸为92.7nm,高EE为94.24%。 FFIR,H-1 NMR和DSC证明了BCA单体的完全聚合,药物在NPS内部以分子或无定形形式。来自HCPT-PBCA-NPS的体外释放药物展示持续释放,透析在透析的24小时内从NPS释放小于60%的HCPT。蜂窝摄取性研究显示,NPS的Caco-2细胞摄取因活性内吞作物,克拉仑和Caveolin介导的过程来治理,并随着NPS浓度的增加而增加。大鼠的药代动力学研究表明,与HCPT悬浮液相比,将HCPT与PBCA-NPS的封装分别增加C-MAX和AUC(0-T)约6.52和7.56倍。得出结论是,通过微乳液聚合制备的HCPT负载PBCA-NP可以在口服药物递送方面具有前景。 (c)2017 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号